Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival - PubMed
8 hours ago
- #biomarkers
- #proteomics
- #ALS
- Proteomic profile of CSF at diagnosis determines ALS progression and survival.
- CXCL7 identified as a promising complementary biomarker for ALS.
- Study used SWATH-MS proteomics and LC-MS/MS lipidomics on CSF samples.
- WPCNA revealed modular proteomic signatures capturing ALS heterogeneity.
- CXCL7 levels associated with survival time and localized in motor neurons.
- Proteomic profiles distinguished ALS patients from controls and stratified by survival.
- Lipidomic profiles showed limited discriminatory power in ALS.
- Machine learning models developed for optimal biomarker panels.
- Findings support improved patient stratification and personalized therapeutic strategies.